Annabel Maruani
4
Documents
Identifiants chercheurs
- annabel-maruani
- ResearcherId : L-9017-2015
- IdRef : 088646270
- 0000-0003-3734-810X
- ResearcherId : http://www.researcherid.com/rid/L-9017-2015
Présentation
Publications
- 4
- 4
- 4
- 3
- 3
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 2
- 2
|
Research Techniques Made Simple: Randomized~Controlled Trials for Topical Drugs in~Dermatology: When~and How Should We Use a~Within-Person Design?Journal of Investigative Dermatology, 2020, 140 (5), pp.931-938.e1. ⟨10.1016/j.jid.2020.03.945⟩
Article dans une revue
hal-03159474v1
|
|
Efficacy and safety of methotrexate versus placebo as add-on therapy to H1 antihistamines for patients with difficult-to-treat chronic spontaneous urticaria: A randomized, controlled trialJournal of The American Academy of Dermatology, 2020, 82 (1), pp.240-243. ⟨10.1016/j.jaad.2019.07.097⟩
Article dans une revue
hal-02623128v1
|
|
Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial.Trials, 2019, 20 (1), ⟨10.1186/s13063-019-3767-8⟩
Article dans une revue
hal-02622848v1
|
Evaluation of a low-dose methotrexate added to h1-antihistamines regimen for severe chronic spontaneous urticaria: a phase III, randomized, placebo-controlled trial24. World Congress of dermatology (WCD 2019), Jun 2019, Milan, Italy
Communication dans un congrès
hal-02736447v1
|